Iron and the anaemia of chronic disease: a review and strategic recommendations

References

• Caro JJ, Salas M, Ward A, et al. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer 2001;91:2214–21
   PubMed Web of Science ®Google Scholar
• Locatelli F, Pisoni RL, Akizawa T, et al. Anemia management for hemodialysis patients: Kidney Disease Outcomes Quality Initiative (K/DOQI) guidelines and Dialysis Outcomes and Practice Patterns Study (DOPPS) findings. Am J Kidney Dis 2004;44:27–33
   PubMed Web of Science ®Google Scholar
• Vogelzang NJ, Breitbart W, Cella D, et al. Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The Fatigue Coalition. Semin Hematol 1997;34:4–12
   PubMed Web of Science ®Google Scholar
• Berndt E, Kallich J, McDermott A, et al. Reductions in anaemia and fatigue are associated with improvements in productivity in cancer patients receiving chemotherapy. Pharmacoeconomics 2005;23:505–14
   PubMed Web of Science ®Google Scholar
• Basta SS, Soekirman, Karyadi D, et al. Iron deficiency anemia and the productivity of adult males in Indonesia. Am J Clin Nutr 1979;32:916–25
   PubMed Web of Science ®Google Scholar
• Selvaratnam RR, de Silva LD, Pathmeswaran A, et al. Nutritional status and productivity of Sri Lankan tea pluckers. Ceylon Med J 2003;48:114–8
   PubMedGoogle Scholar
• Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 1999;91:1616–34
   PubMed Web of Science ®Google Scholar
• World Health Organization 2006. WHO health topics: anaemia. http://www.who.int/topics/anaemia/en/ [last accessed 10 Feb 2006]
   Google Scholar
• Ludwig H, Van Belle S, Barrett-Lee P, et al. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 2004;40:2293–306
   Google Scholar
• Knight K, Wade S, Balducci L. Prevalence and outcomes of anemia in cancer: a systematic review of the literature. Am J Med 2004;5:11S–26S
   Google Scholar
• Peeters HR, Jongen-Lavrencic M, Raja AN, et al. Course and characteristics of anemia in patients with RA of recent onset. Ann Rheum Dis 1996;55:162–8
   PubMed Web of Science ®Google Scholar
• Wilson A, Yu HT, Goodenough LT, et al. Prevalence and outcomes of anemia in rheumatoid arthritis: a systematic review of the literature. Am J Med 2004;116:50S–57S
   Google Scholar
• Laporte J-R, Ibanez L, Vidal X, et al. Upper gastrointestinal bleeding associated with the use of NSAIDs: newer versus older agents. Drug Safety 2004;27:411–20
   Google Scholar
• Vreugdenhil G, Wognum AW, van Eijk HG, et al. Anaemia in rheumatoid arthritis: the role of iron, vitamin B12, and folic acid deficiency, and erythropoietin responsiveness. Ann Rheum Dis 1990;49:93–8
   PubMed Web of Science ®Google Scholar
• Karhausen T, Anker SD, Doehner W. Anemia in chronic heart failure – clinical and prognostic significance. Curr Med Chem Cardiovasc Hematol Agents 2005;3:297–303
   Google Scholar
• Anand IS, Kuskowski MA, Rector TS, et al. Anemia and change in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure: results from Val-HeFT. Circulation 2005;112:1121–7
   PubMed Web of Science ®Google Scholar
• Belperio PS, Rhew DC. Prevalence and outcomes of anemia in individuals with human immunodeficiency virus: a systematic review of the literature. Am J Med 2004;116:27S–43S
   Google Scholar
• Guralnik JM, Eisenstaedt RS, Ferrucci L, et al. Prevalence of anemia in persons 65 years and older in the United States: evidence for a high rate of unexplained anemia. Blood 2004;104:2263–8
   PubMed Web of Science ®Google Scholar
• Ricketts C, Jacobs A, Cavill I. Ferrokinetics and erythropoiesis in man: the measurement of effective erythropoiesis, ineffective erythropoiesis and red cell lifespan using 59Fe. Br J Haematol 1975;31: 65–75
   Google Scholar
• Bron D, Meuleman N, Mascaux C. Biological basis of anemia. Semin Oncol 2001;28:1–6
   PubMed Web of Science ®Google Scholar
• Cavill I. The rejected reticulocyte. Br J Haematol 2005;84:563–5
   Google Scholar
• Macdougall IC, Cavill I, Hulme B, et al. Detection of functional iron deficiency during erythropoietin treatment: a new approach. Br Med J 1992;304:225–6
   PubMed Web of Science ®Google Scholar
• Glaspy J, Bukowski R, Steinberg D, et al. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice [Procrit Study Group]. J Clin Oncol 1997;1915:1218–34
   Google Scholar
• Demetri GD, Kris M, Wade J, et al. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study [Procrit Study Group]. J Clin Oncol 1998;1916:3412–25
   Google Scholar
• Kaltwasser JP, Arndt U. ACD in inflammatory rheumatic diseases. Anemia of chronic disease. New York: Taylor & Francis; 2005. p. 633–57
   Google Scholar
• Littlewood TJ, Bajetta E., Nortier JWR., et al. Effects of epoetin alfa on hematological parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001;19:2865–74
   Google Scholar
• Cavill I. The need for a blood transfusion service. Transfus Med 2005;15:257
   PubMed Web of Science ®Google Scholar
• Cavill I. Reducing blood transfusion. Br Med J 2002;325:655
   PubMed Web of Science ®Google Scholar
• Peeters HR, Jongen-Lavrencic M, Vreugdenhil G, et al. Effect of recombinant human erythropoietin on anaemia and disease activity in patients with rheumatoid arthritis and anaemia of chronic disease: a randomised placebo controlled double blind 52 week clinical trial. Ann Rheum Dis 2005;55:739–44
   Google Scholar
• Kaltwasser JP, Kessler U, Gottschalk R, et al. Effect of recombinant human erythropoietin and intravenous iron on anemia and disease activity in rheumatoid arthritis. J Rheumatol 2001;28:2340–436
   Google Scholar
• Auerbach M, Ballard H, Trout JR, et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J Clin Oncol 2004;1922:1301–7
   Google Scholar
• Eschbach JW, Egrie JC, Downing MR, et al. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. New Engl J Med 1987;316:73–8
   PubMed Web of Science ®Google Scholar
• Fishbane S, Ungureanu VD, Maesaka JK, et al. The safety of intravenous iron dextran in hemodialysis patients. Am J Kidney Dis 1996;1928:529–34
   Google Scholar
• Macdougall IC, Tucker B, Thompson J, et al. A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int 1996;1950:1694–9
   Google Scholar
• Sargent JA, Acchiardo SR. Iron requirements in hemodialysis. Blood Purif 2004;1922:112–23
   Google Scholar
• Martini A, Ravelli A, Di Fuccia G, et al. Intravenous iron therapy for severe anaemia in systemic-onset juvenile chronic arthritis. Lancet 1994;344:1052–4
   PubMed Web of Science ®Google Scholar
• Cazzola M, Ponchio L, de Benedetti F, et al. Defective iron supply for erythropoiesis and adequate endogenous erythropoietin production in the anemia associated with systemic-onset juvenile chronic arthritis. Blood 1996;87:4824–30
   PubMed Web of Science ®Google Scholar
• Locatelli F, Aljama P, Barany P, et al. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004;19:1–47
   PubMed Web of Science ®Google Scholar
• Auerbach M, Witt D, Toler W, et al. Clinical use of the total dose intravenous infusion of iron dextran. J Lab Clin Med 1988;111:566–70
   PubMed Web of Science ®Google Scholar
• Grasso P. Sarcoma after intramuscular iron injection. Br Med J 1973;16:667
   Google Scholar
• Hamstra RD, Block MH, Schocket AL. Intravenous iron dextran in clinical medicine. J Am Med Assoc 1980;243:1726–31
   PubMed Web of Science ®Google Scholar
• Feldman HI, Joffe M, Robinson B, et al. Administration of parenteral iron and mortality among hemodialysis patients. J Am Soc Nephrol 2004;1915:1623–32
   Google Scholar
• Hoen B, Paul-Dauphin A, Hestin D, et al. EPIBACDIAL: a multicenter prospective study of risk factors for bacteremia in chronic hemodialysis patients. J Am Soc Nephrol 1998;1909:869–76
   Google Scholar
• Chertow GM, Mason PD, Vaage-Nilsen O, et al. On the relative safety of parenteral iron formulations. Nephrol Dial Transplant 2004;19:1571–5
   PubMed Web of Science ®Google Scholar
• Bailie GR, Clark JA, Lane CE, et al. Hypersensitivity reactions and deaths associated with intravenous iron preparations. Nephrol Dial Transplant 2005;20:1443–9
   PubMed Web of Science ®Google Scholar
• Aronoff GR. Safety of intravenous iron in clinical practice: implications for anemia management protocols. J Am Soc Nephrol 2004;15:S99–S106
   Google Scholar
• Weinberg ED. The role of iron in cancer. Eur J Cancer Prev 1996;5:19–36
   PubMed Web of Science ®Google Scholar
• Hershko C, Link G, Tzahor M, et al. The role of iron and iron chelators in anthracycline cardiotoxicity. Leuk Lymphoma 1993;11:207–14
   PubMed Web of Science ®Google Scholar
• Cavill I. The hematologist. ASH Newsletter 2005;2:2
   Google Scholar